NICE draft guidance on tests to target Erbitux better
This article was originally published in Clinica
NICE, the health technology appraisal institute for England and Wales, has published draft guidance recommending a number of tests to help doctors target treatment with Merck KGaA/ Bristol-Myers Squibb 's Erbitux (cetuximab) more effectively in people with advanced (metastatic) colorectal cancer.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.